Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJDYNQ)

Drug Name
E-2007 Drug Info
Synonyms Perampanel; E 2007; Perampanel (USAN); 2-(2-oxo-1-phenyl-5-pyridin-2-yl-pyridin-3-yl)benzonitrile; 3-(2-Cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one
Indication
Disease Entry ICD 11 Status REF
Diabetic neuropathy 8C0Z Approved [1]
Parkinson disease 8A00.0 Discontinued in Phase 3 [1]
Cross-matching ID
PubChem CID
9924495
ChEBI ID
CHEBI:71013
CAS Number
CAS 380917-97-5
TTD Drug ID
DMJDYNQ
INTEDE Drug ID
DR1256
ACDINA Drug ID
D00519

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Glutamate receptor AMPA 1 (GRIA1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NBQX DMPHZI5 Neurological disorder 6B60 Phase 1 [7]
YM-90K DMWRT4L Convulsion 8A68.Z Discontinued in Phase 2 [8]
Farampator DM76GRQ Major depressive disorder 6A70.3 Discontinued in Phase 1 [9]
GYKI-52466 DM3YG5P Alzheimer disease 8A20 Terminated [10]
GYKI-53655 DMC0JN8 N. A. N. A. Terminated [11]
Zonampanel DM70HZD N. A. N. A. Terminated [8]
SORETOLIDE DMTDLHG Convulsion 8A68.Z Terminated [12]
[3H]kainate DMMK7XU Discovery agent N.A. Investigative [13]
DNQX DMQXPA5 Discovery agent N.A. Investigative [14]
RPR-118723 DMLDWCB Discovery agent N.A. Investigative [15]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Glutamate receptor AMPA 2 (GRIA2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Paliroden DMX8ZAQ Parkinson disease 8A00.0 Phase 2 [16]
[3H]CNQX DMIFKUX Discovery agent N.A. Investigative [17]
ATPO DMXLS78 Discovery agent N.A. Investigative [17]
(S)-5-fluorowillardiine DMCIZ7P Discovery agent N.A. Investigative [17]
[3H]AMPA DMLF7SG N. A. N. A. Investigative [17]
Drug(s) Targeting Glutamate receptor AMPA (GRIA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Halothane DM80OZ5 Anaesthesia 9A78.6 Approved [18]
Zopiclone DMPI6Z0 Insomnia 7A00-7A0Z Approved [19]
Sevoflurane DMC9O43 Anaesthesia 9A78.6 Approved [20]
Enflurane DM0YJSB Anaesthesia 9A78.6 Approved [21]
Isoflurane DMY6T31 Anaesthesia 9A78.6 Approved [22]
Bromazepam DMY9TCW Anxiety disorder 6B00-6B0Z Approved [23]
Artemisinin SP DMFETDK Malaria 1F40-1F45 Approved [24]
Dihydroergotoxine DM5D6WZ Alzheimer disease 8A20 Approved [25]
Barbiturate DMJIA6T Anaesthesia 9A78.6 Approved [26]
Fospropofol disodium DMKLJRD Monitored anaesthesia care N.A. Approved [27]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Glutamate receptor AMPA 3 (GRIA3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
[3H]CNQX DMIFKUX Discovery agent N.A. Investigative [28]
ATPO DMXLS78 Discovery agent N.A. Investigative [28]
(S)-5-fluorowillardiine DMCIZ7P Discovery agent N.A. Investigative [28]
[3H]AMPA DMLF7SG N. A. N. A. Investigative [28]
joro toxin DMYBJ4K Discovery agent N.A. Investigative [28]
Drug(s) Targeting Glutamate receptor AMPA 4 (GRIA4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
[3H]CNQX DMIFKUX Discovery agent N.A. Investigative [29]
ATPO DMXLS78 Discovery agent N.A. Investigative [29]
(S)-5-fluorowillardiine DMCIZ7P Discovery agent N.A. Investigative [29]
[3H]AMPA DMLF7SG N. A. N. A. Investigative [29]
joro toxin DMYBJ4K Discovery agent N.A. Investigative [29]
AMG-889436 DMKP8L9 Parkinson disease 8A00.0 Investigative [29]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [30]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [31]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [32]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [33]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [34]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [35]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [36]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [37]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [31]
Verapamil DMA7PEW Angina pectoris BA40 Approved [38]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [39]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [40]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [41]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [42]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [43]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [44]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [36]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [45]
Verapamil DMA7PEW Angina pectoris BA40 Approved [46]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [47]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [48]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [49]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [50]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [51]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [52]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [53]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [54]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [55]
Verapamil DMA7PEW Angina pectoris BA40 Approved [56]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [51]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glutamate receptor AMPA (GRIA) TTAN6JD NOUNIPROTAC Modulator [2]
Glutamate receptor AMPA 1 (GRIA1) TTVPQTF GRIA1_HUMAN Inhibitor [3]
Glutamate receptor AMPA 2 (GRIA2) TT9HLZ0 GRIA2_HUMAN Inhibitor [3]
Glutamate receptor AMPA 3 (GRIA3) TT82EZV GRIA3_HUMAN Inhibitor [3]
Glutamate receptor AMPA 4 (GRIA4) TTPJR0G GRIA4_HUMAN Inhibitor [3]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) Main DME DE4LYSA CP3A4_HUMAN Substrate [4]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [5]
Cytochrome P450 3A5 (CYP3A5) Main DME DEIBDNY CP3A5_HUMAN Substrate [6]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7050).
2 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
3 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
4 The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015 Jan;56(1):12-27.
5 Perampanel (Fycompa): a review of clinical efficacy and safety in epilepsy. P T. 2016 Nov;41(11):683-698.
6 FDA label of Perampanel. The 2020 official website of the U.S. Food and Drug Administration.
7 Structural investigation of the 7-chloro-3-hydroxy-1H-quinazoline-2,4-dione scaffold to obtain AMPA and kainate receptor selective antagonists. Syn... J Med Chem. 2006 Oct 5;49(20):6015-26.
8 Synthesis and AMPA receptor antagonistic activity of a novel 7-imidazolyl-6-trifluoromethyl quinoxalinecarboxylic acid with a substituted phenyl gr... Bioorg Med Chem Lett. 2004 Oct 18;14(20):5107-11.
9 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
10 New 7,8-ethylenedioxy-2,3-benzodiazepines as noncompetitive AMPA receptor antagonists. Bioorg Med Chem Lett. 2006 Jan 1;16(1):167-70.
11 Substituted 1,2-dihydrophthalazines: potent, selective, and noncompetitive inhibitors of the AMPA receptor. J Med Chem. 1996 Jan 19;39(2):343-6.
12 Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl. 2013;(197):19-24.
13 1H-cyclopentapyrimidine-2,4(1H,3H)-dione-related ionotropic glutamate receptors ligands. structure-activity relationships and identification of pot... J Med Chem. 2008 Oct 23;51(20):6614-8.
14 Synthesis of chiral 1-(2'-amino-2'-carboxyethyl)-1,4-dihydro-6,7-quinoxaline-2,3-diones: alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate recep... J Med Chem. 1996 Oct 25;39(22):4430-8.
15 Indeno[1,2-b]pyrazin-2,3-diones: a new class of antagonists at the glycine site of the NMDA receptor with potent in vivo activity. J Med Chem. 2000 Jun 15;43(12):2371-81.
16 Mechanism of inhibition of the GluA2 AMPA receptor channel opening by talampanel and its enantiomer: the stereochemistry of the 4-methyl group on the diazepine ring of 2,3-benzodiazepine derivatives.ACS Chem Neurosci.2013 Apr 17;4(4):635-44.
17 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 445).
18 Reduced inhibition of cortical glutamate and GABA release by halothane in mice lacking the K+ channel, TREK-1. Br J Pharmacol. 2007 Nov;152(6):939-45.
19 Eszopiclone: its use in the treatment of insomnia. Neuropsychiatr Dis Treat. 2007 Aug;3(4):441-453.
20 Effects of sevoflurane on carrageenan- and fentanyl-induced pain hypersensitivity in Sprague-Dawley rats. Can J Anaesth. 2009 Feb;56(2):126-35.
21 Enflurane directly depresses glutamate AMPA and NMDA currents in mouse spinal cord motor neurons independent of actions on GABAA or glycine receptors. Anesthesiology. 2000 Oct;93(4):1075-84.
22 Transmembrane residues define the action of isoflurane at the GABAA receptor alpha-3 subunit. Brain Res. 2005 Jan 25;1032(1-2):30-5.
23 Glutamatergic and GABAergic modulations of ultrasonic vocalizations during maternal separation distress in mouse pups. Psychopharmacology (Berl). 2009 May;204(1):61-71.
24 GABA(A) receptor ligands and their therapeutic potentials. Curr Top Med Chem. 2002 Aug;2(8):817-32.
25 Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97.
26 Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79.
27 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
28 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 446).
29 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 447).
30 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
31 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
32 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
33 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
34 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
35 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
36 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
37 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
38 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
39 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
40 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
41 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
42 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
43 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
44 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
45 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
46 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
47 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
48 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
49 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
50 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
51 Drug Interactions Flockhart Table
52 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
53 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
54 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
55 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
56 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.